Fowkes v Boston Scientific Corporation

Link copied
Case Copied 83 min read

FEDERAL COURT OF AUSTRALIA

Fowkes v Boston Scientific Corporation [2023] FCA 230  

File number: NSD 244 of 2021
Judgment of: LEE J
Date of judgment: 16 March 2023
Catchwords: REPRESENTATIVE PROCEEDINGS – open class representative proceeding brought against manufacturer and supplier of pelvic “mesh” implants – where group members afflicted by physical, psychological and psychosocial difficulties – application under s 33V of the Federal Court of Australia Act 1976 (Cth) to approve settlement – bifurcation of question of approval of settlement and distribution of settlement sum – where hundreds of group member objections received – whether headline figure fair and reasonable inter partes and inter se – relevance of non-admission of liability – settlement approved
Legislation:

Competition and Consumer Act 2010 (Cth) Pt VIB, ss 87L, 87M, 87P(1), 87P(2), 87Q, 87S, 87V

Evidence Act 1995 (Cth) Pt 2.1, Div 2, ss 9(1), 9(2)(c), 21(1), 136, 190

Federal Court of Australia Act 1976 (Cth) Pt IVA, ss 25(6), 33V(1), 33V(2), 54A

Health and Other Services (Compensation) Act 1995 (Cth)

Judiciary Act 1903 (Cth) s 79

National Disability Insurance Scheme Act 2013 (Cth)

Social Security Act 1991 (Cth)

Trade Practices Act 1974 (Cth)

Veteran’s Entitlements Act 1986 (Cth)

Civil Law (Wrongs) Act 2002 (ACT) s 98

Civil Liability Act 1936 (SA) s 54

Civil Liability Act 2002 (NSW) ss 12, 12(3)

Civil Liability Act 2002 (Tas) s 25

Civil Liability Act 2002 (WA) ss 11, 11(3)

Civil Liability Act 2003 (Qld) s 54

Personal Injuries (Liabilities and Damages) Act 2003 (NT) ss 18, 20

Wrongs Act 1958 (Vic) ss 28F, 28F(3)

Cases cited:

Abbott v Zoetis Australia Pty Ltd (No 2) [2019] FCA 462; (2019) 369 ALR 512

Australian Competition and Consumer Commission v Chats House Investments Pty Limited (1996) 71 FCR 250

Australian Securities and Investments Commission v Richards [2013] FCAFC 89

Blairgowrie Trading Ltd v Allco Finance Group Ltd (recs and mgrs apptd) (in liq) (No 3) [2017] FCA 330; (2017) 343 ALR 476

Botsman v Bolitho [2018] VSCA 278; (2018) 57 VR 68

Camilleri v The Trust Company (Nominees) Limited [2015] FCA 1468

Clark v National Australia Bank Limited (No 2) [2020] FCA 652

Darwalla Milling Co Pty Ltd v F Hoffman-LA Roche Ltd (No 2) [2006] FCA 1388; (2007) 236 ALR 322

Davis v Quintis Ltd (Subject to Deed of Company Arrangement) [2022] FCA 806

Dyczynski v Gibson [2020] FCAFC 120; (2020) 280 FCR 583

Ethicon Sàrl v Gill [2021] FCAFC 29; (2021) 288 FCR 338

Gill v Ethicon Sàrl (No 10) [2023] FCA 228

Gill v Ethicon Sàrl (No 11) [2023] FCA 229

Gill v Ethicon Sàrl (No 2) [2019] FCA 177; (2019) 134 ACSR 649

Gill v Ethicon Sàrl (No 5) [2019] FCA 1905

John Pfeiffer Pty Ltd v Rogerson [2000] HCA 36; (2000) 203 CLR 503

Kelly v Willmott Forests Ltd (in liquidation) (No 4) [2016] FCA 323; (2016) 335 ALR 439

King v AG Australia Holdings Ltd [2002] FCA 872; (2002) 121 FCR 480

LCM…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Fowkes v Boston Scientific Corporation and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2023] FCA 230
Decision Date

CaseChat Overview and Summary

The case of Fowkes v Boston Scientific Corporation was brought against the manufacturer and supplier of pelvic “mesh” implants by a group of individuals who experienced physical, psychological, and psychosocial difficulties. The proceedings were an open class representative proceeding, and the applicants sought approval of a settlement under section 33V of the Federal Court of Australia Act 1976 (Cth). The court had to determine whether the settlement terms were fair and reasonable, and if the settlement should be approved despite the absence of an admission of liability by the defendant.

The legal issues before the court were twofold: first, whether the settlement terms were fair and reasonable in all respects, particularly given the hundreds of objections raised by group members; and second, whether the court should bifurcate the question of approval of the settlement from the distribution of the settlement sum. The court had to balance the need for finality in the proceedings with the rights of group members who had not yet suffered complications from the implants.

In reaching its decision, the court considered the broad range of complications experienced by the group members and the potential for late-onset complications. The court noted that the proposed settlement scheme included payments to all recipients of the implants, regardless of whether they had suffered complications. The court found that the settlement was fair and reasonable inter partes and inter se, despite the absence of an admission of liability. The court also approved the bifurcation of the settlement approval and distribution issues, directing that the distribution be determined at a later date.

The court's final orders included the approval of the settlement on the terms set out in the Settlement Deed, subject to the later determination of distribution orders. The court also directed that submissions be made regarding the appointment of a referee to administer the settlement and stood over the proceedings for a case management hearing. The court's decision was guided by the need to ensure that the settlement adequately addressed the claims of all group members, including those at risk of late-onset complications.

Orders

Orders of the court

1. Pursuant to s 33V(1) of the Federal Court of Australia Act 1976 (Cth) (FCA Act), the settlement of the proceedings between the parties on the terms set out in the Settlement Deed executed 12 July 2022 (as varied by the Deed of Variation of Settlement Deed executed 26 October 2022) be approved.

2. The settlement approval in Order 1 is subject to the separate and later determination of what orders should be made as are just with respect to the distribution of the money paid under the settlement pursuant to s 33V(2) of the FCA Act.

3. Within seven days any party opposing the appointment of a referee to put the administration of the settlement to tender file and serve submissions.

4. The proceeding be stood over for a case management hearing on a date to be fixed.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Thirdly, a notable aspect of Shine’s proposed scheme is that all recipients of the implants qualify for payment, including those who have not suffered, or not yet suffered, a complication. But those who are not suffering a complication are still at risk of a late onset complication. As such, a troubling aspect of any proposed settlement of this proceeding is ensuring it is calibrated to the sensitives associated with late onset complications. The price of any settlement with Boston is meeting the requirement of finality, including by capturing the claims of group members up to the cut-off date even if their compensable claims have not yet arisen.I CONCLUSION I will make orders giving effect to these reasons, and await any submissions from the parties as to the appropriateness of putting the settlement administration to tender.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.